Annovis Bio, Inc. (ANVS)

NYSE: ANVS · IEX Real-Time Price · USD
9.79
+0.92 (10.37%)
At close: Feb 27, 2024, 4:00 PM
9.98
+0.19 (1.94%)
After-hours: Feb 27, 2024, 7:36 PM EST
10.37%
Market Cap 93.84M
Revenue (ttm) n/a
Net Income (ttm) -37.09M
Shares Out 10.58M
EPS (ttm) -4.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 263,798
Open 8.81
Previous Close 8.87
Day's Range 8.70 - 9.88
52-Week Range 5.42 - 23.89
Beta 1.65
Analysts Strong Buy
Price Target 33.67 (+243.92%)
Earnings Date Apr 1, 2024

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2020
Employees 5
Stock Exchange NYSE
Ticker Symbol ANVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price forecast is $33.67, which is an increase of 243.92% from the latest price.

Price Target
$33.67
(243.92% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel p...

19 hours ago - GlobeNewsWire

Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease

MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last pa...

13 days ago - GlobeNewsWire

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio

MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing o...

4 weeks ago - GlobeNewsWire

Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement

MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postpo...

4 weeks ago - GlobeNewsWire

Annovis Bio to Participate in the 139th Yale CEO Summit

BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD)...

2 months ago - GlobeNewsWire

Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease

BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last pat...

3 months ago - GlobeNewsWire

Annovis Bio Appoints Andrew Walsh as Vice President Finance

BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD)...

3 months ago - GlobeNewsWire

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections

BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's dis...

3 months ago - GlobeNewsWire

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, inc...

3 months ago - GlobeNewsWire

Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson's Patients

BERWYN, Pa.--(BUSINESS WIRE)--Recent developments in biomarker research have enabled the performance of measurements of important biomarkers in plasma rather than in CSF (cerebrospinal fluid), making ...

4 months ago - Business Wire

Annovis Bio Announces Pricing of $7.5 Million Public Offering

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including...

4 months ago - Business Wire

Annovis Bio Announces Launch of Proposed Public Offering

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including...

4 months ago - Business Wire

Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer's Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidat...

4 months ago - Business Wire

Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's...

4 months ago - Business Wire

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's ...

Other symbols: AVTXMTNBTPST
4 months ago - Invezz

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's Study

Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer's Disease (AD) is sufficiently powered to continue as planned without any ...

4 months ago - GlobeNewsWire

Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's...

7 months ago - Business Wire

Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's...

8 months ago - Business Wire

Annovis Bio Announces the Filing of a Groundbreaking Patent

BERWYN, Pa.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), a clinical stage drug platform company developing novel and transformative therapies for neurodegenerative diseases, announces the creatio...

8 months ago - Business Wire

Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson's Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)

BERWYN, PA.--(BUSINESS WIRE)--Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for earl...

9 months ago - Business Wire

Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace

BERWYN, Pa. , June 8, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease...

9 months ago - PRNewsWire

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first...

10 months ago - GlobeNewsWire

Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans

BERWYN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing treatments for neurodegenerative diseases announced today t...

10 months ago - GlobeNewsWire

ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST

Company to hold R&D webcast today at 4:00 pm ET to review ongoing clinical programs in Alzheimer's disease and Parkinson's disease Updated Webcast link and dial-in information are provided below BERWY...

11 months ago - PRNewsWire

ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST

Phase 2/3 AD Study continues to make steady progress in patient recruitment Company to hold R&D webcast on Thursday, April 20 th to review ongoing clinical programs in Alzheimer's disease and Parkinso...

11 months ago - PRNewsWire